scholarly journals A rare case of drug-induced hypersensitivity syndrome by pirfenidone for idiopathic pulmonary fibrosis

2018 ◽  
Vol 67 (3) ◽  
pp. 425-426 ◽  
Author(s):  
Kumiko Suda ◽  
Koji Kamiya ◽  
Binluen Chiang ◽  
Hirofumi Okada ◽  
Naoko Mato ◽  
...  
Author(s):  
Masaki Tominaga ◽  
Masaki Okamoto ◽  
Takashi Kinoshita ◽  
Yuki Sakazaki ◽  
Masanobu Matsuoka ◽  
...  

2017 ◽  
Author(s):  
Lawrence A Ho ◽  
Bridget F Collins ◽  
Ganesh Raghu

Idiopathic lung diseases are diffuse parenchymal lung diseases that are grouped under the term interstitial lung disease (ILD). The term interstitial (or interstitium) is, however, misleading as the term interstitium refers to the microscopic anatomic space between the basement membranes of the endothelial and epithelial cells. The pathologic processes involved in these diseases, however, are not limited to the interstitium and can affect other elements of the gas exchange units as well as bronchiolar lumen, terminal bronchioles, pulmonary parenchyma, and pleural and vascular spaces. Since there are potentially hundreds of agents and clinical situations that are associated with ILD, a simplified grouping scheme includes seven main entities: ILD associated with (1) occupational and environmental factors (inhalation cause), (2) collagen vascular diseases, (3) granulomatous lung disease of known and unknown causes (eg, hypersensitivity pneumonitis [HP], sarcoidosis), (4) inherited diseases, (5) iatrogenic/drug induced, (6) certain specific entities (eg, pulmonary Langerhans cell histiocytosis [PLCH], lymphangioleimyomatosis, and (7) idiopathic interstitial pneumonia (IIP). As idiopathic pulmonary fibrosis (IPF) is a subgroup of IIP, this review focuses on the clinical features and management of the major IIPs, and IPF is discussed more in the review, “Idiopathic Pulmonary Fibrosis,” found elsewhere in this publication. This review also focuses on HP as it is a key disease in the differential diagnosis of the IIPs. Figures depict chest radiographs, high resolution computed topography (HRCT) scans, and histopathologic features of various ILDs. Tables list the American Thoracic Society (ATS) and the European Respiratory Society (ERS) classification of IIPs, and common antigens associated with HP and their potential sources. This review contains 22 highly rendered figures, 2 tables, and 156 references.


2011 ◽  
Vol 2011 (jun23 1) ◽  
pp. bcr0420114061-bcr0420114061 ◽  
Author(s):  
R. C. Anakwue ◽  
C. P. Chijioke ◽  
N. I. Iloanusi

2017 ◽  
Author(s):  
Lawrence A Ho ◽  
Bridget F Collins ◽  
Ganesh Raghu

Idiopathic lung diseases are diffuse parenchymal lung diseases that are grouped under the term interstitial lung disease (ILD). The term interstitial (or interstitium) is, however, misleading as the term interstitium refers to the microscopic anatomic space between the basement membranes of the endothelial and epithelial cells. The pathologic processes involved in these diseases, however, are not limited to the interstitium and can affect other elements of the gas exchange units as well as bronchiolar lumen, terminal bronchioles, pulmonary parenchyma, and pleural and vascular spaces. Since there are potentially hundreds of agents and clinical situations that are associated with ILD, a simplified grouping scheme includes seven main entities: ILD associated with (1) occupational and environmental factors (inhalation cause), (2) collagen vascular diseases, (3) granulomatous lung disease of known and unknown causes (eg, hypersensitivity pneumonitis [HP], sarcoidosis), (4) inherited diseases, (5) iatrogenic/drug induced, (6) certain specific entities (eg, pulmonary Langerhans cell histiocytosis [PLCH], lymphangioleimyomatosis, and (7) idiopathic interstitial pneumonia (IIP). As idiopathic pulmonary fibrosis (IPF) is a subgroup of IIP, this review focuses on the clinical features and management of the major IIPs, and IPF is discussed more in the review, “Idiopathic Pulmonary Fibrosis,” found elsewhere in this publication. This review also focuses on HP as it is a key disease in the differential diagnosis of the IIPs. Figures depict chest radiographs, high resolution computed topography (HRCT) scans, and histopathologic features of various ILDs. Tables list the American Thoracic Society (ATS) and the European Respiratory Society (ERS) classification of IIPs, and common antigens associated with HP and their potential sources. This review contains 22 highly rendered figures, 2 tables, and 156 references.


Introduction 222 Known idiopathic pulmonary fibrosis 222 Other idiopathic interstitial lung diseases 223 Drug-induced interstitial lung disease 224 Hypersensitivity pneumonitis (HP) 224 The classification of interstitial lung disease (ILD) has been refined significantly over recent years and is rather confusing to the uninitiated! Most ILDs are rare and unlikely to present as an emergency. Cryptogenic fibrosing alveolitis (CFA), also known as idiopathic pulmonary fibrosis (IPF), is probably the most frequent ILD encountered in routine respiratory practice. The pathology underlying this is termed ‘usual interstitial pneumonia’ (UIP) and it is one of the so-called ‘idiopathic interstitial pneumonias’ (IIPs). These three terms (IPF, CFA, UIP) are often used interchangeably in the same patient's notes which can easily cause further confusion! Description of the pathological distinction between specific disease entities is beyond the scope of this chapter (see OHRM, Chapter 35)....


Respiration ◽  
2008 ◽  
Vol 75 (3) ◽  
pp. 350-354 ◽  
Author(s):  
Hideaki Yamasawa ◽  
Yukihiko Sugiyama ◽  
Masashi Bando ◽  
Shoji Ohno

2017 ◽  
Vol 55 (5) ◽  
pp. 293-299 ◽  
Author(s):  
Masaki Tominaga ◽  
Masaki Okamoto ◽  
Tomotaka Kawayama ◽  
Masanobu Matsuoka ◽  
Shinjiro Kaieda ◽  
...  

2021 ◽  
Vol 13 ◽  
pp. 1759720X2110225
Author(s):  
Hiroshi Furukawa ◽  
Shomi Oka ◽  
Takashi Higuchi ◽  
Kota Shimada ◽  
Atsushi Hashimoto ◽  
...  

Interstitial lung disease (ILD) is frequently a complication of rheumatoid arthritis (RA) as an extra-articular manifestation which has a poor prognosis. Acute-onset diffuse ILD (AoDILD) occasionally occurs in RA and includes acute exacerbation of ILD, drug-induced ILD, and Pneumocystis pneumonia. AoDILD also confers a poor prognosis in RA. Previously-established biomarkers for ILD include Krebs von den lungen-6 and surfactant protein-D originally defined in patients with idiopathic pulmonary fibrosis; the sensitivity of these markers for RA-associated ILD (RA-ILD) is low. Although many studies on ILD markers have been performed in idiopathic pulmonary fibrosis, only a few validation studies in RA-ILD or AoDILD have been reported. Biomarkers for RA-ILD and AoDILD are thus still required. Recently, genomic, cytokine, antibody, and metabolomic profiles of RA-ILD or AoDILD have been investigated with the aim of improving biomarkers. In this review, we summarize current preliminary data on these potential biomarkers for RA-ILD or AoDILD. The development of biomarkers on RA-ILD has only just begun. When validated, such candidate biomarkers will provide valuable information on pathogenesis, prognosis, and drug responses in RA-ILD in future.


Sign in / Sign up

Export Citation Format

Share Document